Utilisation des biothérapies dans le psoriasis modéré à sévère : expérience du service de dermatologie du CHU de Besançon (2004–2008)

[1]  P. V. D. van de Kerkhof,et al.  Three‐year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome , 2009, The British journal of dermatology.

[2]  C. Griffiths,et al.  Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre , 2009, The British journal of dermatology.

[3]  J. Ortonne,et al.  Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study , 2008 .

[4]  M. D. de Rie,et al.  Review and expert opinion on prevention and treatment of infliximab‐related infusion reactions , 2008, The British journal of dermatology.

[5]  H. Jacobe,et al.  Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta‐analysis of randomized controlled trials , 2008, The British journal of dermatology.

[6]  F. Aubin,et al.  Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. , 2008, Arthritis and rheumatism.

[7]  E. D. De Jong,et al.  Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome , 2008, The British journal of dermatology.

[8]  S. Rogers,et al.  Two years of experience with etanercept in recalcitrant psoriasis , 2007, The British journal of dermatology.

[9]  I. Potouridou,et al.  The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital , 2007, The British journal of dermatology.

[10]  S. Chimenti,et al.  Long‐term treatment of plaque psoriasis with efalizumab: an Italian experience , 2007, The British journal of dermatology.

[11]  J. Carrascosa,et al.  Managing moderate‐to‐severe psoriasis with efalizumab: experience at a single Spanish institute , 2007, The British journal of dermatology.

[12]  A. Gottlieb,et al.  Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. , 2006, Journal of the American Academy of Dermatology.

[13]  A. Gottlieb,et al.  Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy , 2006, The Journal of dermatological treatment.

[14]  A. Gottlieb,et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.

[15]  A. Gottlieb,et al.  A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. , 2007, Journal of the American Academy of Dermatology.